argenx SE 2021 AR2
The report highlights argenx's transition into a commercial-stage immunology company following the FDA approval of VYVGART (efgartigimod alfa-fcab) for generalized myasthenia gravis (gMG) in December 2021, followed by approval in Japan in January 2022. The company expanded its pipeline with clinical trials ongoing across multiple indications and initiated a Phase 2 trial for ARGX-117. Additionally, argenx grew its workforce to 650 employees and raised $1.15 billion in a global offering, ending the year with a strong cash position of $2.3 billion. The report also includes non-financial disclosures on diversity, equity, and inclusion, noting a 40% female representation in company leadership.
Company: argenx SE
Sector: Manufacturing
Country: Netherlands
Year: 2021
Type: AR2
Pages: 167
Back to company
argenx SE
Annual Report
The report highlights argenx's transition into a commercial-stage immunology company following the FDA approval of VYVGART (efgartigimod alfa-fcab) for generalized myasthenia gravis (gMG) in December 2021, followed by approval in Japan in January 2022. The company expanded its pipeline with clinical trials ongoing across multiple indications and initiated a Phase 2 trial for ARGX-117. Additionally, argenx grew its workforce to 650 employees and raised $1.15 billion in a global offering, ending the year with a strong cash position of $2.3 billion. The report also includes non-financial disclosures on diversity, equity, and inclusion, noting a 40% female representation in company leadership.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2021
Reporting Period
Jan 1, 2021 - Dec 31, 2021
Fiscal Year
2021
Published
Mar 21, 2022
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Women on Board
Women in Management
Employees